Author

Krishna Kalyan Kolluri

Observed names: K Kolluri, K. Kolluri, KK Kolluri, Kolluri, K, Kolluri, Krishna K., Krishna K Kolluri, Krishna K. Kolluri, Krishna Kolluri

Institution: University College London

Observed institutions: University of London, University College London

ORCID: 0000-0003-3537-0231

Observed ORCID: 0000-0003-3537-0231

OpenAlex ID: A5012779200

TRAIL delivery by MSC‐derived extracellular vesicles is an effective anticancer therapy

2017 · ZhengQiang Yuan, Krishna K. Kolluri, et al. · Journal of Extracellular Vesicles · 201

PDF

Mesenchymal stromal cell delivery of full-length tumor necrosis factor–related apoptosis-inducing ligand is superior to soluble type for cancer therapy

2015 · ZhengQiang Yuan, Krishna K. Kolluri, et al. · Cytotherapy · 70

PDF

Systemic but not topical TRAIL-expressing mesenchymal stem cells reduce tumour growth in malignant mesothelioma

2014 · Elizabeth K Sage, Krishna K Kolluri, et al. · Thorax · 69

PDF

Lung delivery of MSCs expressing anti-cancer protein TRAIL visualised with 89Zr-oxine PET-CT

2020 · P. Stephen Patrick, Krishna K. Kolluri, et al. · Stem Cell Research & Therapy · 60

PDF

CADM1 inhibits squamous cell carcinoma progression by reducing STAT3 activity

2016 · Sabari Vallath, Elizabeth K. Sage, et al. · Scientific Reports · 43

PDF

Comprehensive Pharmacogenomic Profiling of Malignant Pleural Mesothelioma Identifies a Subgroup Sensitive to FGFR Inhibition

2017 · Josine M. Quispel-Janssen, Jitendra Badhai, et al. · Clinical Cancer Research · 42

PDF

Cryopreservation of human mesenchymal stromal cells expressing TRAIL for human anti-cancer therapy

2016 · Zhengqiang Yuan, Sofia Da Silva Lourenco, et al. · Cytotherapy · 41

PDF

LRIG1 regulates cadherin‐dependent contact inhibition directing epithelial homeostasis and pre‐invasive squamous cell carcinoma development

2012 · Liwen Lu, Vitor H Teixeira, et al. · The Journal of Pathology · 40

PDF

Representation of genomic intratumor heterogeneity in multi-region non-small cell lung cancer patient-derived xenograft models

2024 · Robert E. Hynds, Ariana Huebner, et al. · Nature Communications · 37

PDF

Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells

2018 · Krishna Kalyan Kolluri, Constantine Alifrangis, et al. · eLife · 31

Mesenchymal Stem Cells as Vectors for Lung Cancer Therapy

2013 · Krishna K. Kolluri, Geoff J. Laurent, et al. · Respiration · 31

Engineered human mesenchymal stem cells for neuroblastoma therapeutics

2019 · Valentina Nieddu, Roberta Piredda, et al. · Oncology Reports · 25

PDF

Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma

2023 · Gaurav Kumar Pandey, Nick Landman, et al. · Cell Reports Medicine · 23

PDF

Retrospective response analysis of BAP1 expression to predict the clinical activity of systemic cytotoxic chemotherapy in mesothelioma

2018 · Neelam Kumar, Doraid Alrifai, et al. · Lung Cancer · 17

PDF

BAP1 and YY1 regulate expression of death receptors in malignant pleural mesothelioma

2021 · Yuki Ishii, Krishna K. Kolluri, et al. · Journal of Biological Chemistry · 12

Lentiviral expression of wild-type LAMA3A restores cell adhesion in airway basal cells from children with epidermolysis bullosa

2024 · Chun Hang Lau, Maral J. Rouhani, et al. · Molecular Therapy · 11

TACTICAL: A phase I/II trial to assess the safety and efficacy of MSCTRAIL in the treatment of metastatic lung adenocarcinoma.

2019 · Alice Davies, Beth Sage, et al. · Journal of Clinical Oncology · 11

Non-Invasive Longitudinal Bioluminescence Imaging of Human Mesoangioblasts in Bioengineered Esophagi

2019 · Claire Crowley, Colin R. Butler, et al. · Tissue Engineering Part C Methods · 9

PDF

TRAIL Coated Genetically Engineered Immunotherapeutic Nano‐Ghosts Vesicles Target Human Melanoma‐Avoiding the Need for High Effective Therapeutic Concentration of TRAIL

2021 · Lior Levy, Tzila Davidov, et al. · Advanced Functional Materials · 5

PDF

Targeted stem cells expressing TRAIL as a therapy for lung Cancer TACTICAL: a phase I/II trial

2018 · E. Sage, A. Davies, et al. · Lung Cancer · 4

PDF

High throughput therapeutic screening of malignant pleural mesothelioma (MPM) to identify correlation of sensitivity to FGFR inhibitors with BAP1 inactivation.

2015 · Constantine Alifrangis, Josine Quispel Janssen, et al. · Journal of Clinical Oncology · 4

A first-in-human phase I clinical trial investigating the safety and efficacy of repeat dosing MSCTRAIL cell therapy in addition to chemotherapy and immunotherapy in patients with advanced lung cancer

2026 · Rebecca N. Graham, Alice Davies, et al. · Cytotherapy · 2

PDF

S128 Reduction of lung metastasis by engineered Mesenchymal stem cells expressing secreted soluble TRAIL

2013 · ZQY Yuan, KK Kolluri · Thorax · 2

PDF

S127 Chemotherapy sensitises Malignant pleural mesothelioma cells to undergo MSC-TRAIL induced apoptosis: Abstract S127 Table 1.

2013 · KK Kolluri, E Sage, et al. · Thorax · 2

PDF

S60 Mesenchymal stem cells expressing TRAIL induce apoptosis in malignant pleural mesothelioma

2011 · E. Sage, K. Kolluri, et al. · Thorax · 2

PDF

Works count: 64

Citation count: 801

H-index: 14

I10-index: 17